NCT04861896

Brief Summary

The purpose of this study is to examine the feasibility and preliminary efficacy of a psychosocial eHealth intervention designed to improve hormone therapy adherence among Hispanic/Latinx women with breast cancer. Our proposed secondary outcomes are health-related quality of life and self-efficacy in managing hormone therapy side effects. The intervention components include breast cancer knowledge, hormone/endocrine therapy knowledge, stress awareness and management, social support, and enhanced communication and intimacy skills. The intervention will be delivered via a Smartphone application over a 12-week period. All participants will receive the intervention application (described below). Aside from using the Smartphone application for the recommended 12 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), 6-week follow-up, and 12-week follow-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
26 days until next milestone

First Posted

Study publicly available on registry

April 27, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 25, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 7, 2023

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

1.6 years

First QC Date

March 31, 2021

Last Update Submit

November 7, 2023

Conditions

Outcome Measures

Primary Outcomes (10)

  • Acceptability of My Guide: Usefulness

    To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

    T3 (immediately following 12 week intervention)

  • Acceptability of My Guide: Satisfaction

    To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

    T3 (immediately following 12 week intervention)

  • Acceptability of My Guide: Learnability

    To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

    T3 (immediately following 12 week intervention)

  • Acceptability of My Guide: Usability

    To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

    T3 (immediately following 12 week intervention)

  • Demand of My Guide: Recruitment Rate

    We assess demand of the My Guide application through study recruitment. Based on previous psychosocial and behavioral studies in oncology, an 70% recruitment rate is considered an adequate level of demand.

    12 weeks

  • Demand of My Guide: Retention Rate

    Another way we assess demand of the My Guide application is through participant retention. Based on previous psychosocial and behavioral studies in oncology, an 70% retention rate is considered an adequate level of demand.

    12 weeks

  • Participant use of My Guide: Number of Login's

    We assess participant use of the My Guide application by examining the number of participant logins to the web-based application.

    12 weeks

  • Participant use of My Guide: Duration of Usage

    We assess participant use of the My Guide application by examining the duration participant time spent on the website. Based on previous psychosocial and behavioral studies in oncology, an average of 8 hours of use is considered an adequate level of engagement.

    12 weeks

  • Participant use of My Guide: Content Accessed

    We assess participant use of the My Guide application by examining the type of content accessed by participants on the website.

    12 weeks

  • Change in Medication adherence will be assessed primarily with the Adherence to Refills and Medication Scale (ARMS).

    The ARMS (Adherence to Refills and Medications Scale) survey is a previously validated patient-report measure of barriers to medication adherence and adherence-related behavior.

    T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)

Secondary Outcomes (2)

  • Change in Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy (FACT-G7)

    T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)

  • Change in Patient Self-Efficacy in managing side effects is measured using the PROMIS Self Efficacy for Managing Symptoms

    T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)

Study Arms (1)

"My Guide" (psychoeducation & self management program)

EXPERIMENTAL

Smartphone-based program plus standard clinical care.

Behavioral: "My Guide" (psychoeducation & self-management program)

Interventions

12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.

"My Guide" (psychoeducation & self management program)

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female
  • Diagnosis of breast cancer, non-metastatic, stage 0-III (A, B, or C)
  • Receiving or received endocrine/hormone therapy within the last 3 years (36 months)
  • At least 18 years of age
  • Able to speak and read English or Spanish
  • Able to provide informed consent
  • Self-identify Hispanic/Latina ethnicity

You may not qualify if:

  • Stage IV or metastatic
  • Visual, hearing, voice, or motor impairment that would prevent completion of study procedures
  • Diagnosis of an unmanaged psychotic disorder, bipolar disorder, dissociative disorder, or other diagnoses for which participation in this trial is either inappropriate or dangerous - this includes patients who have a life-threatening illness (e.g., end-stage kidney disease) or diagnosis of a chronic disease that is associated with a major functional impairment (e.g., fibromyalgia)
  • Illicit substance or alcohol dependence
  • Suicidal ideation, plan, intent
  • Alzheimer's, dementia, or history of stroke
  • Scheduled reconstruction surgery within 1 month of any study procedures or involvement.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Breast NeoplasmsNeoplasms, Hormone-DependentMedication Adherence

Interventions

Self-Management

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

RehabilitationHealth ServicesHealth Care Facilities Workforce and Services

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 31, 2021

First Posted

April 27, 2021

Study Start

April 1, 2021

Primary Completion

October 25, 2022

Study Completion

November 7, 2023

Last Updated

November 8, 2023

Record last verified: 2023-11

Locations